Interestingly, a study conducted by Lee et al. demonstrated that FK866, a NAMPT inhibitor, selectively kills gastric cancer cells with an epithelial–mesenchymal transition gene signature due to their deficiency in NAPRT, which makes them reliant on NAMPT for NAD synthesis. This evidence concerns the gene NAPRT and gastric cancer.